Single high-dose etoposide and melphalan with non-cryopreserved autologous marrow rescue as primary therapy for relapsed, refractory and poor-prognosis Hodgkin's disease.

摘要: A simplified schedule of high-dose chemotherapy (HDC) consisting melphalan (140 mg m-2) plus VP16 (2.5 g given over 12-18 h together with autologous non-cryopreserved bone marrow transplant (ABMT) was used for treatment relapsed (37 patients) and refractory (seven patients as first-line (four poor-prognosis Hodgkin's disease. Two had a second HDC-ABMT after relapse following prior HDC-ABMT, giving total 50 procedures among 48 patients. The haematological recovery rate 98% complete response the disease > 90%. Factors significantly influencing were performance status presence liver involvement. Thirty-nine are alive, 37 in continuous remission. median duration survival remission have not been reached at follow-up time 45 months. Adverse prognostic factors (refractory versus relapse, primarily showing poor survival) High-dose short-duration is an effective safe modality